Can a liposomal chemo combo outsmart tough leukemias?

NCT ID NCT07735117

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 3 trial compares two drug combinations for adults with a high-risk form of myelodysplastic syndrome (MDS-IB2) or newly diagnosed acute myeloid leukemia (AML) that is either secondary to prior treatment or occurs in older age. One group receives a standard regimen of azacitidine plus venetoclax, while the other gets a newer combination: mitoxantrone hydrochloride liposome, cytarabine, G-CSF, and venetoclax. The main goal is to see which approach leads to a higher rate of complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of mitoxantrone hydrochloride liposome, cytarabine, G-CSF, and venetoclax
What this could lead to: If successful, this could offer a more effective treatment option for people with high-risk MDS or AML who are older or have secondary disease, potentially improving remission rates.
What could go wrong: This is an early-phase trial with a relatively small number of participants. The combination therapy may cause significant side effects, and it is not yet known if it will lead to better long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts-2 Myelodysplastic Syndromes therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML) MYELODYSPLASTIC SYNDROMES (MDS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.